AstraZeneca

Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
Yahoo/Motley Fool
drug pricing
Big Pharma
Amgen
AstraZeneca
Pfizer
GSK
Merck
Gilead
Flag link:
Women in Science: AstraZeneca
Women in Science: AstraZeneca
Pharmaforum
women executives
women
AstraZeneca
Flag link:
AstraZeneca Departures Continue as Medical Chief Bohen Exits
AstraZeneca Departures Continue as Medical Chief Bohen Exits
Bloomberg
AstraZeneca
reorganization
Flag link:
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
JP Morgan Healthcare Conference Update: Sage, Mersana, Shutdown Woes and Babies
BioSpace
JPMHC 2019
SAGE Therapeutics
SAGE-217
Mersana
Novavax
Denali Therapeutics
AstraZeneca
Amarin
FDA
government shutdown
Flag link:
AstraZeneca chops 210 workers, closes sites as it looks to concentrate biologics manufacturing in one place
AstraZeneca chops 210 workers, closes sites as it looks to concentrate biologics manufacturing in one place
Endpoints
AstraZeneca
layoffs
drug manufacturing
Colorado
Flag link:
AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure
AstraZeneca rejigs commercial ranks around cancer, biopharma in wake of Mallon's departure
Fierce Pharma
AstraZeneca
reorganization
oncology
restructuring
Flag link:
Ironwood names AstraZeneca exec as CEO; shares up 8%
Ironwood names AstraZeneca exec as CEO; shares up 8%
Seeking Alpha
Ironwood Pharmaceuticals
AstraZeneca
Mark Mallon
Flag link:
New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases
New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases
BioSpace
breast cancer
lung cancer
AstraZeneca
Tagrisso
Novartis
Gleevec
Tasigna
Bristol-Myers Squibb
Sprycel
Pfizer
Bosulif
Takeda
Iclusig
Flag link:
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
Yahoo/Zacks.com
Myriad Genetics
AstraZeneca
BRACAnalysis CDx
diagnostics
Lynparza
Flag link:
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
FDA hands AstraZeneca and Merck a snap OK to market Lynparza in frontline ovarian cancer, marking a new standard in treatment
Endpoints
AstraZeneca
Merck
Lynparza
BRCA-mutated ovarian cancer
FDA
Flag link:
AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial
AstraZeneca mines for positives in Imfinzi's failed Mystic lung cancer trial
Fierce Pharma
AstraZeneca
Imfinizi
clinical trials
immuno-oncology
Flag link:
AZ begins liver cancer immunotherapy tie-up with AVEO
AZ begins liver cancer immunotherapy tie-up with AVEO
Pharmaforum
AstraZeneca
Aveo Oncology
cancer immunotherapy
Imfinzi
Fotivda
hepatocellular carcinoma
Flag link:
AstraZeneca looks to CRISPR to boost success rates
AstraZeneca looks to CRISPR to boost success rates
Pharmaforum
AstraZeneca
CRISPR
drug development
Flag link:
AstraZeneca kicks off second blood cancer launch, this time for orphan drug Lumoxiti
AstraZeneca kicks off second blood cancer launch, this time for orphan drug Lumoxiti
Fierce Pharma
AstraZeneca
drug launches
Lumoxiti
hairy cell leukemia
Flag link:
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
AstraZeneca's Imfinzi fails another phase 3 trial, this time in head and neck cancer
Fierce Pharma
AstraZeneca
Imfinzi
head and neck cancer
clinical trials
Flag link:
AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma
AstraZeneca divests asthma and rhinitis drug rights to Covis Pharma
Pharmaceutical Business Review
AstraZeneca
Covis Pharma
asthma
Flag link:
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
Xconomy
GSK
M&A
Tesaro
PARP inhibitors
Zejula
AstraZeneca
Flag link:
Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails to Meet Endpoints in Phase IIa Trial
Asthma Drug Co-Developed by Dynavax and AstraZeneca Fails to Meet Endpoints in Phase IIa Trial
BioSpace
asthma
Dynavax
AstraZeneca
clinical trials
AZD1419
Flag link:
Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease
Astrazeneca's Fasenra Gets Orphan Drug Designation for Autoimmune Disease
Yahoo/Zacks.com
AstraZeneca
Fasenra
orphan drugs
FDA
eosinophilic granulomatosis with polyangiitis
Flag link:

Pages